Ubs Oconnor LLC Biotechnology

Ubs Oconnor LLC

$1.46 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
OVID Ovid Therapeutics Inc.	$46.5M	$741,000 0.05% of portfolio	628,290	Q3 2024 Added 117.94%
CNTB Connect Biopharma Holdings LTD	$53.4M	$735,000 0.05% of portfolio	510,701	Q1 2024 Reduced 9.0%
VKTX Viking Therapeutics, Inc.	$2.6B	$716,000 0.05% of portfolio	11,316	Q3 2024 New
THRD Third Harmonic Bio, Inc.	$212M	$708,000 0.05% of portfolio	52,294	Q3 2024 Added 6.18%
DYN Dyne Therapeutics, Inc.	$736M	$693,000 0.05% of portfolio	19,318	Q3 2024 Reduced 41.36%
ARVN Arvinas, Inc.	$937M	$674,000 0.05% of portfolio	27,403	Q3 2024 Reduced 9.56%
ITOS I Teos Therapeutics, Inc.	$268M	$673,000 0.05% of portfolio	65,940	Q3 2024 Added 86.68%
VRNA Verona Pharma PLC	$3.51B	$648,000 0.04% of portfolio	22,541	Q3 2024 New
MIRM Mirum Pharmaceuticals, Inc.	$1.8B	$644,000 0.04% of portfolio	16,538	Q3 2024 Reduced 56.58%
XNCR Xencor Inc	$1.09B	$643,000 0.04% of portfolio	32,000	Q3 2024 New
CNTX Context Therapeutics Inc.	$14.5M	$605,000 0.04% of portfolio	308,758	Q3 2024 Added 5.11%
PCVX Vaxcyte, Inc.	$5.24B	$605,000 0.04% of portfolio	5,307	Q3 2024 Reduced 15.86%
EWTX Edgewise Therapeutics, Inc.	$1.77B	$533,000 0.04% of portfolio	20,000	Q3 2024 Reduced 76.47%
ALLK Allakos Inc.	$20.3M	$505,000 0.03% of portfolio	777,702	Q3 2024 Added 8.53%
MRUS Merus N.V.	$1.88B	$495,000 0.03% of portfolio	9,922	Q3 2024 Added 10.24%
RCUS Arcus Biosciences, Inc.	$931M	$487,000 0.03% of portfolio	31,862	Q3 2024 Reduced 51.12%
VTYX Ventyx Biosciences, Inc.	$114M	$436,000 0.03% of portfolio	200,000	Q3 2024 New
ARDX Ardelyx, Inc.	$849M	$418,000 0.03% of portfolio	60,736	Q3 2024 Reduced 28.2%
TERN Terns Pharmaceuticals, Inc.	$177M	$400,000 0.03% of portfolio	48,000	Q3 2024 New
BDTX Black Diamond Therapeutics, Inc.	$99.2M	$394,000 0.03% of portfolio	90,706	Q3 2024 Reduced 70.13%
NERV Minerva Neurosciences, Inc.	$12.3M	$286,000 0.02% of portfolio	107,256	Q3 2024 Added 7.41%
VERU Veru Inc.	$44.9M	$253,000 0.02% of portfolio	329,861	Q3 2024 Added 10.24%
APLS Apellis Pharmaceuticals, Inc.	$3.19B	$219,000 0.01% of portfolio	7,603	Q3 2024 New
ERAS Erasca, Inc.	$231M	$191,000 0.01% of portfolio	70,000	Q3 2024 New
IMUX Immunic, Inc.	$29.3M	$177,000 0.01% of portfolio	107,685	Q3 2024 Reduced 8.5%
SVRA Savara Inc	$308M	$163,000 0.01% of portfolio	38,482	Q3 2024 Reduced 12.5%
ALT Altimmune, Inc.	$326M	$135,000 0.01% of portfolio	22,048	Q3 2024 Reduced 44.88%
CCCC C4 Therapeutics, Inc.	$170M	$131,000 0.01% of portfolio	23,000	Q3 2024 New
HLVX Hille Vax, Inc.	$65.9M	$91,000 0.01% of portfolio	51,779	Q3 2024 Added 10.24%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.